The US Food and Drug Administration has approved its first drug for peanut allergies in children. The drug AR101, or Palforzia, uses oral immunotherapy, with children given tiny but increasing amounts of peanut protein over a six-month period under medical supervision. After that, users must continue to take a daily dose to be able to tolerate accidental exposure to nuts. Scientists have however said, the treatment is not a cure and the risk of a potentially fatal anaphylactic reaction remains. Palforzia, which has been approved for use in patients aged between four and 17, comes in the form of a powder which is sprinkled on food.